Popular Articles

N.C. Bill Gives Students 'Vital Access' To Accurate Sex Education Instruction, Editorial States
A bill (S. 221) approved by the North Carolina Legislature that would require a public school sex education curriculum covering abstinence, contraception and sexually transmitted infections "will be the most comprehensive and science-based approach the state has used" for sex education, a Charlotte Observer editorial states, adding that Gov. Bev Perdue (D) "should sign it." The bill would require all public school districts in the state to teach a curriculum that focuses on abstinence but also includes information on preventing pregnancy and STIs. Parents would be able to have their children removed from the comprehensive portions of instruction. According to the editorial, the measure "still gives parents a choice in deciding what kind of sex education their children will receive." The editorial adds, "It also finally provides a curriculum that gives N.C. students vital access to age-appropriate, science-based information critical to their health, safety and well-being," which is "the kind of information that can help them make smart choices in serious situations."Parents are "often the best people for kids to turn to for advice and information" on sex, but "not all children have parents who can provide it, or are even willing to," and "not all children [who] go to their parents adhere to their advice," the editorial states. It continues, "The schools provide another avenue to get this critical advice and information -- and state lawmakers are right to make it available." According to the Observer, North Carolina has the ninth-highest teenage pregnancy rate in the U.S., and about "20,000 teenagers will get pregnant in North Carolina this year." A "comprehensive, science-based education program can help reduce the number of unintended teen pregnancies" and help reduce the spread of STIs, the editorial says. It concludes, "By reaching agreement on this matter, state lawmakers have given the children of this state vital tools to safeguard their health and welfare. ... Perdue should sign this bill and make it law" (Charlotte Observer, 6/26).
new payday loan lenders
Buy zoloft and forget about depression.
Clear Innova Launches Innovative Radiology Information System
Clear Innova announced the launch of a next-generation radiology information system (RIS) that will serve as an efficient, cost-effective practice management solution for imaging centers and hospital radiology departments.
News of the day
Sinovac Receives Revised Approvals For Panflu
Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it has received a revised Drug Supplementary Application Approval for Panflu(TM), Sinovac"s pandemic influenza vaccine from the China State Food and Drug Administration (SFDA), based on the Phase IIb clinical trial, Under the revised approval, the age group eligible for use of the whole viron inactivated pandemic influenza vaccine was expanded to 18 years old and over, whereas it was previously 18 to 60 years of age, enabling Sinovac to reach a much broader percentage of the population.
Medical Devices

MedImmune Funds Study To Help Gain Insights Into Full Burden Of RSV Disease Among Premature Infants

MedImmune continues to advance its commitment to pediatric research with today"s announcement of the first observational prospective study designed to assess the burden of respiratory syncytial virus (RSV) among preterm infants 32-to-35 weeks gestational age (GA) in outpatient settings during their first year of life. The study also seeks to gather virology data regarding the national onset of the RSV season across the four geographic regions established by the U.S. Centers for Disease Control & Prevention. Additionally, this two-year observational study will look to identify the preterm infants that may be most susceptible to serious RSV infection and the factors that may elevate that risk. "More than 98 percent of all children contract RSV before their second birthday. Some of these children will be hospitalized and for many more, the severity of the infection forces them to visit a healthcare provider or hospital clinic on an outpatient basis," said Jessie Groothuis, M.D., MedImmune vice president, medical and scientific affairs, infectious disease. "The intent of this first-of-its-kind prospective study is to add to the body of evidence surrounding RSV burden of disease; gaining a snapshot of when the RSV season starts and stops; as well as gathering insight into what risk factors may make preterm infants most susceptible to RSV infection and to serious RSV-related illness." She went on to say that this information may help pediatricians, payers and health policy makers make better decisions regarding the use of finite healthcare res on behalf of under-represented and under-served 32-to-35 weeks (GA) preterm infants. This observational, prospective study will cover two consecutive RSV seasons and begin patient enrollment in fall 2009, with a target of 3,000 participants across 100 outpatient sites in the United States. The study population will include infants born 32-to-35 weeks (GA) who do not receive RSV prophylaxis during their first RSV season. About RSV Each year, up to 125,000 infants in the United States are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in U.S. infants. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups. A recent study published in the New England Journal of Medicine found that RSV accounts for one of every 13 visits to a pediatrician, one of every 38 emergency room trips, and inpatient hospital stays for one out of every 334 children. About MedImmune MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. MedImmune


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):